Cite
Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
MLA
Aisagbonhi, Omonigho, et al. “Comprehensive Next-Generation Sequencing Identifies Novel Putative Pathogenic or Likely Pathogenic Germline Variants in Patients with Concurrent Tubo-Ovarian and Endometrial Serous and Endometrioid Carcinomas or Precursors.” Gynecologic Oncology, vol. 187, Aug. 2024, pp. 241–48. EBSCOhost, https://doi.org/10.1016/j.ygyno.2024.05.027.
APA
Aisagbonhi, O., Ghlichloo, I., Hong, D. S., Roma, A., Fadare, O., Eskander, R., Saenz, C., Fisch, K. M., & Song, W. (2024). Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors. Gynecologic Oncology, 187, 241–248. https://doi.org/10.1016/j.ygyno.2024.05.027
Chicago
Aisagbonhi, Omonigho, Ida Ghlichloo, Duncan S. Hong, Andres Roma, Oluwole Fadare, Ramez Eskander, Cheryl Saenz, Kathleen M. Fisch, and Wei Song. 2024. “Comprehensive Next-Generation Sequencing Identifies Novel Putative Pathogenic or Likely Pathogenic Germline Variants in Patients with Concurrent Tubo-Ovarian and Endometrial Serous and Endometrioid Carcinomas or Precursors.” Gynecologic Oncology 187 (August): 241–48. doi:10.1016/j.ygyno.2024.05.027.